For a long time, we have been concentrating on the protein HER2
but now we have this gene that could be responsible for the spread of the cancer.
These observations have provided a strong rationale for inhibition of both EGFR and HER2
in the treatment of HER2
-positive tumours and have led to the development of lapatinib, which is a small-molecule, dual tyrosine-kinase inhibitor of EGFR and HER2
currently approved for use in HER2
-positive breast cancer.
HERmark provides accurate and quantitative measurements of HER2
total protein levels and HER2
The study also showed 30% of clinicians admitted HER2
status was rarely available and missing HER2
results led to extra out-patient visits in 46% of responses.
First, important clinical data presented demonstrates the superiority of HERmark over FISH testing for HER2
In 20 to 30 percent of breast cancer eases, overproduction of HER2
stimulates cell proliferation.
gene produces a specific protein found on a cell's surface that acts like an antenna, receiving signals to grow.
Perjeta is designed specifically to prevent the HER2
receptor from pairing (or "dimerizing") with other HER receptors (EGFR/HER1, HER3 and HER4) on the surface of cells, a process that is believed to play a role in tumor growth and survival.
These pooled data show the overall survival benefit of eribulin in the important and often forgotten about HER2
negative and triple negative subtypes, who constitute the majority of patients with cancer.
status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
Around 15% of breast cancers are HER2
-positive, The new drug, from Roche Holding AG, attaches to the HER2
growth receptor and blocks signals that encourage the cancer to grow and spread.
In addition, FISH testing has the ability to detect aneuploidy that may reflect both an adverse overall prognosis and the likelihood of downstream HER2